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ABSTRACT
Objectives It is unclear how newer methods of respiratory 
support for infants born extremely preterm (EP; 22–27 
weeks gestation) have affected in- hospital sequelae. 
We aimed to determine changes in respiratory support, 
survival and morbidity in EP infants since the early 1990s.
Design Prospective longitudinal cohort study.
Setting The State of Victoria, Australia.
Participants All EP births offered intensive care in four 
discrete eras (1991–1992 (24 months): n=332, 1997 (12 
months): n=190, 2005 (12 months): n=229, and April 
2016–March 2017 (12 months): n=250).
Outcome measures Consumption of respiratory 
support, survival and morbidity to discharge home. Cost- 
effectiveness ratios describing the average additional days 
of respiratory support associated per additional survivor 
were calculated.
Results Median duration of any respiratory support 
increased from 22 days (1991–1992) to 66 days (2016–
2017). The increase occurred in non- invasive respiratory 
support (2 days (1991–1992) to 51 days (2016–2017)), 
with high- flow nasal cannulae, unavailable in earlier 
cohorts, comprising almost one- half of the duration in 
2016–2017. Survival to discharge home increased (68% 
(1991–1992) to 87% (2016–2017)). Cystic periventricular 
leukomalacia decreased (6.3% (1991–1992) to 1.2% 
(2016–2017)), whereas retinopathy of prematurity 
requiring treatment increased (4.0% (1991–1992) to 
10.0% (2016–2017)). The average additional costs 
associated with one additional infant surviving in 
2016–2017 were 200 (95% CI 150 to 297) days, 326 (183 
to 1127) days and 130 (70 to 267) days compared with 
1991–1992, 1997 and 2005, respectively.
Conclusions Consumption of resources for respiratory 
support has escalated with improved survival over time. 
Cystic periventricular leukomalacia reduced in incidence 
but retinopathy of prematurity requiring treatment 
increased. How these changes translate into long- 
term respiratory or neurological function remains to be 
determined.
INTRODUCTION
Modern neonatal intensive care initiatives 
starting from the 1970s led to increased 
survival of infants born extremely preterm 
(EP, 22–27 weeks gestation) in high- income 
countries by the early 1990s.1 These included 
respiratory support after birth, antenatal 
corticosteroids to mature fetal lungs, exog-
enous surfactant to treat respiratory distress 
syndrome and an increased willingness of 
clinicians to offer intensive care.
Strengths and limitations of this study
 ► This is one of the few reports of how changes in 
respiratory support practice since the introduction of 
surfactant, and different oxygen targets in preterm 
newborns have affected short term outcomes in 
whole populations.
 ► Strengths of the study include sequential cohorts 
from the same defined geographical area, with 
uniform data collection by experienced teams, and 
standards of care that are consistent within the re-
gion at any one time.
 ► Limitations include the equal weighting for all meth-
ods for respiratory support in determining cost- 
effectiveness ratios.
 ► We were unable to determine changing rates of 
bronchopulmonary dysplasia using more contem-
porary definitions because such criteria were not 
present for the earlier cohorts.
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Respiratory distress syndrome is the most common 
early morbidity faced by EP infants, and new strategies 
for respiratory support and oxygen targeting have been 
introduced since the early 1990s.2 The focus has shifted 
to using more non- invasive respiratory support, including 
nasal continuous positive airway pressure (nCPAP) and 
more recently, high- flow nasal cannulae (HFNC). The 
rationale behind non- invasive respiratory support has 
been the persistently high rates of bronchopulmonary 
dysplasia (BPD) in EP infants3–5 and the belief that non- 
invasive methods would facilitate earlier extubation, or 
even avoid intubation entirely, and thus reduce the risk of 
developing BPD. Individual randomised trials of early use 
of non- invasive respiratory support have not consistently 
demonstrated a reduction in BPD6 7 but a meta- analysis 
suggested that there may be a benefit for survival and less 
BPD with the combination of non- invasive ventilation 
and surfactant.8 However, the meta- analysis was limited 
by the overall poor quality of evidence, heterogeneity of 
the non- invasive ventilation strategies, and lack of robust 
high- quality randomised trials. With these changes in 
respiratory support, it is important to clarify the relation-
ships between the consumption of respiratory resources 
and outcomes. Randomised trials of different oxygen 
saturation targets have reported increased survival but 
also increased rates of retinopathy of prematurity (ROP) 
with higher oxygen saturation targets (91%–95%) rather 
than lower targets (85%–89%).9
Monitoring changes in perinatal outcomes with 
advances in clinical care is vital, as outcomes reported in 
randomised trials may not translate into improvements 
in whole populations. In Victoria, Australia, four distinct 
geographical cohorts of EP infants have been recruited 
into longitudinal research studies since the early 1990s 
which coincided with the introduction of surfactant,10 
enabling in- hospital and long- term outcomes of EP 
infants to be monitored over time in relation to advances 
in neonatal care. Thus, the aims of this study were to 
determine over the 25 years period: (1) the changes in 
respiratory support, survival to discharge home and major 
respiratory and non- respiratory neonatal morbidities of 
EP infants offered intensive care and (2) the consumption 
of respiratory resources in relation to changes in survival. 
We hypothesised that the consumption of resources for 
respiratory support would be similar over time, but the 
proportion of invasive mechanical ventilation would be 
lower, and that HFNC would supersede the use of nCPAP. 
We also hypothesised that there would be improved 
survival and less BPD in the most recent (2016–2017) 
cohort compared with earlier eras.
PATIENTS AND METHODS
Data were derived from prospective longitudinal 
cohort studies of all EP infants in the state of Victoria, 
Australia, during four discrete periods: 1 January 
1991–31 December 1992 (24 months), 1 January–31 
December 1997 (12 months), 1 January–31 December 
2005 (12 months), and 1 April 2016–31 March 2017 (12 
months). These studies were a collaborative effort of all 
four tertiary neonatal units, the government data collec-
tion agencies and the state- wide newborn emergency 
retrieval service in Victoria, which have existed since the 
1970s. Perinatal outcomes for the three earlier cohorts 
have been reported.11 Denominators for all 22–27 week 
births were obtained from the Victorian Perinatal Data 
Collection which collects data prospectively on all births 
in the state of Victoria.12 Written informed consent was 
obtained from the parents of the survivors born in 2005 
and 2016–2017. Perinatal data collection and follow- up 
were considered routine clinical care for EP children in 
the earlier cohorts.
Perinatal and neonatal data collection
Perinatal, neonatal and maternal data were collected 
prospectively. Gestational age at birth was confirmed by 
obstetric ultrasound before 20 weeks and available for 
>90% of pregnancies, or by menstrual history if not avail-
able. We obtained data on all births, including stillbirths 
and live births with lethal anomalies for completeness, 
but our focus was on live births free of lethal anomalies 
who were offered intensive care, defined as receiving 
respiratory support or other lifesaving interventions after 
birth. Lethal anomalies were defined as major malforma-
tions coded according to the International Classification 
of Diseases13 for which survival was not possible even 
with provision of neonatal intensive care. Inborn status 
refers to births in a tertiary perinatal centre. Birthweight 
z- scores were computed relative to the British Growth 
Reference for all eras, for consistency.14 Serial cranial 
ultrasonography was routine in all eras; intraventricular 
haemorrhage (IVH) was recorded as the worst grade on 
either side according to Papile et al,15 and cystic periven-
tricular leukomalacia was defined as any cystic lesions in 
the periventricular white matter. We documented dura-
tion of respiratory support, including different types (ie, 
‘invasive’ respiratory support comprising intermittent 
positive- pressure ventilation and high- frequency oscilla-
tory ventilation, both delivered through an endotracheal 
tube; and ‘non- invasive’ respiratory support comprising 
nCPAP and HFNC at rates of greater than 2 L/min), and 
duration of supplemental oxygen therapy. Treatment for 
ROP included cryotherapy, laser therapy, or bevacizumab 
injections, the last of which was only available for the 
2016–2017 cohort. Postnatal corticosteroid use referred to 
any corticosteroids (usually dexamethasone) prescribed 
to prevent or treat BPD, but did not include corticoste-
roids (usually hydrocortisone) used only to treat hypoten-
sion. BPD was defined as oxygen dependency at 36 weeks 
corrected age for consistency across all eras because the 
definition of BPD has altered over time.16
STATISTICAL METHODS
Data were analysed using Stata Release V.15 (StataCorp). 
Participant characteristics and neonatal data were 
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compared between eras (with the 2016–2017 cohort as 
the reference) using linear or logistic regressions, fitted 
using generalised estimating equations and reported with 
robust (sandwich) estimates of SEs to account for clus-
tering because of multiple births within the same family. 
The consumption of respiratory resources in participants 
offered intensive care was compared between eras using 
quantile regression, with the 2016–2017 cohort as the 
reference. Comparisons between eras of consumptions of 
resources, neonatal morbidities and survival were adjusted 
for potential covariates known at time of birth, that is, 
inborn status, gestation at birth, sex and birthweight 
z- score. Since survivors consume more resources than 
do infants who die, we repeated the analyses including 
only survivors to discharge to ensure that the increased 
consumption of resources over time was not merely due 
to increased survival rates.
The added duration of respiratory support per addi-
tional survivor in 2016–2017 was calculated relative to 
each of the other eras. These are known as incremental 
cost- effectiveness ratios, and were calculated as the differ-
ence in cost (days of respiratory support at the patient 
level in 2016–2017 compared with other eras) divided by 
the difference in effectiveness (survival outcome at the 
patient level in 2016–2017 compared with other eras) 
and are interpreted as the average additional costs asso-
ciated with one additional infant surviving. A higher 
incremental cost- effectiveness ratio is less favourable 
compared with a lower ratio. To account for sampling 
uncertainty, a bootstrapping method with 1000 replica-
tions drawing from costs and effectiveness at the patient 
level was used to estimate the mean and the 95% CI of 
the cost- effectiveness ratios, where the 95% CIs were esti-
mated using the 2.5 and 97.5 percentiles.17 Each of the 
1000 replications represents one mean cost and effective-
ness result from a random sampling with replacement of 
the original sample. The bootstrapped results were also 
presented using cost- effectiveness planes. In the event that 
any of the simulations were ‘dominated’ (ie, they repre-
sented both greater costs and poorer outcomes), they 
were excluded from the calculations because the negative 
incremental cost- effectiveness ratios they produce are not 
interpretable.17
Denominators varied from all live births free of lethal 
anomalies, all those offered intensive care, all survivors 
to 36 weeks only, and all survivors to discharge only, 
depending on the research question being addressed. 
Given the multiple comparisons, we have interpreted our 
findings by focusing on overall patterns and magnitude of 
differences, rather than on individual p values.
Patient and public involvement
The Consumer Advisory Group of the National Health 
and Medical Research Council of Australia Centre 
of Research Excellence in Newborn Medicine will be 
involved in the planning and execution of knowledge 
translation and dissemination of this research. There was 
no patient or public involvement in the design, planning 
or conception of the study.
RESULTS
Participant characteristics
The numbers of total births, stillbirths, live births, 
including those with lethal anomalies and those who 
did not receive intensive care in each era are shown in 
figure 1. The proportion of stillbirths in relation to all 
births fell over time, from 39.2% in 1991–1992 to 23.3% 
in 2016–2017. The proportion of infants who received 
intensive care was lower in 1991–1992 compared with 
2016–2017 (OR 0.60, 95% CI 0.39 to 0.91, p=0.02), partic-
ularly for infants born 23 and 24 completed weeks (see 
online supplementary figure 1A). No infant born 22 
weeks received intensive care in 2016–2017 (see online 
supplementary figure 1A, figure 1, table 1).
Stillbirths, live births, including those with lethal anom-
alies and those who did not receive intensive care in each 
era, are shown in figure 1. The proportion of stillbirths in 
relation to all births fell over time, from 39.2% in 1991–
1992 to 23.3% in 2016–2017. The proportion of infants 
who received intensive care was lower in 1991–1992 
compared with 2016–2017 (OR 0.60, 95% CI 0.39 to 0.91, 
p=0.02), particularly for infants born 23 and 24 completed 
weeks (see online supplementary figure 1A). No infant 
born 22 weeks received intensive care in 2016–2017 (see 
online supplementary figure 1A, figure 1, table 1).
Among infants who received intensive care, the propor-
tion of infants born in a tertiary perinatal centre was 
higher in both 1991–1992 and 1997 than in 2016–2017 
(table 1). Antenatal corticosteroid treatment and rates of 
caesarean birth were lowest in 1991–1992, but were similar 
to that of 2016–2017 from 1997 onwards. Rates of intu-
bation at birth were higher in all earlier eras compared 
with 2016–2017. There were no differences between eras 
in multiple births, male sex, gestational age, birth weight 
or birthweight z- score.
Durations of resources for respiratory support, oxygen 
therapy and hospitalisation
Duration of all respiratory support was shorter in earlier 
eras compared with 2016–2017, with the adjusted 
Figure 1 Numbers of births, stillbirths, live births with 
and without lethal anomalies, and live births free of lethal 
anomalies offered intensive care in each era.
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difference in medians ranging from −24 to −36 days. 
The differences were accounted for by an increase in 
non- invasive respiratory support over time. HFNC was 
only available in 2016–2017 and it comprised almost 
50% of non- invasive respiratory support in that era. 
HFNC, however, was not accompanied by any decrease 
in the duration of nCPAP in 2016–2017 compared with 
2005. The median durations of supplemental oxygen 
were shorter in earlier eras compared with 2016–2017, 
by adjusted differences between −17 to −24 days. Dura-
tions of hospital stay were shorter in 1991–1992 and 1997 
compared with 2016–2017 (table 2).
Postnatal corticosteroids to prevent or treat BPD 
were less common in 2005 compared with 2016–2017. 
A reverse trend was observed for BPD, with higher 
rates in 2005 compared with 2016–2017. ROP requiring 
treatment was lower in earlier eras compared with 
2016–2017.
When analyses were repeated for infants born EP who 
survived to discharge home only, the conclusions were 
similar with several exceptions. The median days of 
nCPAP in 2005 were higher compared with 2016–2017 
and the evidence for shorter durations of supplemental 
oxygen in earlier eras compared with 2016–2017 weak-
ened (see online supplementary table 1).
In-hospital survival, treatments and morbidities
Survival to discharge home was lower in earlier eras 
compared with 2016–2017, but the evidence was weakest 
for a difference compared with 1997. A similar trend 
was observed with survival free of major morbidities, as 
defined by having one or more of IVH grade 3–4, cystic 
periventricular leukomalacia, necrotising enterocolitis, 
ROP requiring treatment or BPD. Within each week of 
gestational age, the higher survival rate in 2016–2017 was 
most consistently evident in the 24 and 25 weeks groups 
(see online supplementary figure 1B,C). The median 
durations of hospital stay for those who died were similar 
across eras (median days (IQR; 25th–75th centiles) 1991–
1992: 4 (1–13); 1997: 3 (1–17); 2005: 14 (2–69); 2016–
2017: 6 (1–20)), and much lower than for infants who 
survived (tables 2 and 3).
Compared with 2016–2017, surfactant treatment was 
less common in 1991–1992, but was more common in 
2005. Cystic periventricular leukomalacia in survivors was 
more common in earlier eras compared with 2016–2017, 
but the evidence was strongest for differences with 1991–
1992 and 1997. Rates of IVH grade 3–4 and surgery were 
similar across eras.
As no infants born at 22 weeks gestation received 
intensive care in 2016–2017, analyses for tables 2 and 
3 were repeated for infants born 23–27 weeks only 
Table 2 Durations of respiratory support, oxygen therapy and hospitalisation in those who received intensive care
1991–92 1997 2005 2016–2017*




CI), p value† Median (IQR)
Adj diff. 
medians (95% 









22 (4–41) −36 (−41 to –31), 
p<0.001
42 (20–61) −24 (−31 to –18), 
p<0.001






16 (3–31) 8 (4 to 12), 
p<0.001
15 (4–30) 4 (−1 to 9), 
p=0.08







2 (0–9) −48 (−52 to –45), 
p<0.001
21 (8–35) −30 (−34 to –26), 
p<0.001






2 (0–9) −23 (−27 to –19), 
p<0.001
21 (8–35) −4 (−9 to 0.3), 
p=0.07




























82 (19–104) −13 (−20 to –6), 
p<0.001
93 (68–112) −9 (−17 to –1), 
p=0.03




*2016–2017 cohort as a reference for all comparisons.
†Adjusted for inborn status (ie, birth in a tertiary perinatal centre), gestation at birth, sex, birthweight z- score.
‡Includes positive pressure ventilation via endotracheal tube, high frequency oscillatory ventilation.
§Includes positive pressure ventilation via endotracheal tube, high frequency oscillatory ventilation, nCPAP and HFNC.
¶Includes nCPAP and HFNC.
**Until discharge home.
Diff. medians, difference in medians; HFNC, high- flow nasal cannulae; nCPAP, nasal continuous positive airway pressure.
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(see online supplementary tables 2 and 3), with similar 
conclusions.
Cost-effectiveness ratios: increments in durations of 
respiratory support associated with one extra infant surviving
The average additional cost associated with one additional 
infant surviving was estimated to be 200 (95% CI 150 to 
297) days of respiratory support in 2016–2017 compared 
with 1991–1992 (figure 2). Similarly, in 2016–2017 relative 
to 1997, there were 326 (95% CI 183 to 1127) additional 
days of respiratory support for one additional survival 
achieved. There were 2.6% of the replications in figure 2 
falling in the north west quadrant, which were excluded 
from the estimated incremental cost- effectiveness ratio to 
obtain a meaningful 95% CI for the remaining 97.2% of 
the replications (the excluded replications are available 
in figure 2). The additional days of respiratory support 
associated with an additional infant surviving in 2016–
2017 relative to 2005 were estimated to be 130 (95% CI 
70 to 267) days (figure 2).
Using the above cost- effectiveness ratios, each addi-
tional cot dedicated for respiratory support in 2016–2017 
led to 1.8 additional survivors compared with 1991–1992 
(365/200), 1.1 additional survivors compared with 1997 
(365/326), and 2.8 additional survivors compared with 
2005 (365/130).
DISCUSSION
In this geographical study of infants born EP across four 
eras since the introduction of surfactant into clinical 
care, there was an escalating consumption of resources 
for respiratory support, in particular non- invasive respi-
ratory support. Survival to discharge home, duration of 
supplemental oxygen therapy, and rates of ROP requiring 
treatment all increased, whereas rates of cystic periven-
tricular leukomalacia decreased. BPD reduced between 
2005 and 2016–2017, reversing the rise observed previ-
ously up to 2005.18 Over time, there were fewer stillbirths, 
more EP births outside a tertiary centre, more antenatal 
corticosteroid treatment, more infants offered intensive 
care, more caesarean births and less intubation at birth 
in those offered intensive care. Surfactant treatment rose 
between 1991and 1992 and 2005, then fell in 2016–2017, 
whereas the converse was observed for postnatal cortico-
steroid therapy.
The increase in EP survival from the current study is 
in keeping with trends worldwide over a similar time 
period.5 19 20 There were no 22 weeks infants offered 
intensive care in the most recent era, practice that can 
in part be explained by a 2006 consensus statement in 
Australia21 whereby initiation of resuscitation for infants 
born prior to 23 weeks was not recommended based on 
high morbidity and mortality.
Since the late 2000s, non- invasive respiratory support 
has been the preferred mode for infants born EP. Our 
experience of fewer infants being intubated in the delivery 
room in 2016–2017 than in earlier eras has been observed 
elsewhere,19 reflecting newer approaches to neonatal 
resuscitation worldwide.22 As expected, the duration of 
‘invasive’ respiratory support with an endotracheal tube 
decreased substantially between 1991–1992 and 2016–
2017, mirrored by an increase in the duration of ‘non- 
invasive’ respiratory support. What was surprising was 
the use of HFNC, which was mostly additive rather than 
an alternative to the use of nCPAP. This would suggest 
that the thresholds for commencement and cessation of 
HFNC are lower than those for nCPAP, despite both being 
forms of ‘gentler’ non- invasive respiratory support. There 
were no standard criteria for commencement or cessa-
tion of nCPAP or HFNC, which were at the discretion of 
the treating clinicians. In the short term, the prolonged 
use of HFNC adds to the consumption of intensive care 
resources as the staff and equipment required to care 
for an infant on HFNC are greater than for infants on 
low flow oxygen or no respiratory support and are equiv-
alent to the requirements for infants on nCPAP in our 
nurseries. In addition, the increase in survival rates alone 
across the eras was not responsible for the increased 
overall consumption of respiratory support in EP infants.
We expressed the cost- effectiveness ratios in resource 
units (days of respiratory support per additional survivor) 
rather than monetary units to put in context how much 
additional resources associated with respiratory support 
would be expected for any increase in survival rates of 
infants born EP. Considering the substantial value of 
an infant’s life, the additional investment in respiratory 
support in recent years is likely worthwhile. It is possible 
that HFNC, available only in 2016–2017, was overused, 
which is supported by the fact that days of HFNC were 
mostly additive to days of nCPAP in 2016–2017. We have 
previously reported that efficiency of neonatal intensive 
care for infants born 500–999 g birth weight in the state 
of Victoria between 1979 and 1997 was relatively stable, 
and at lower cost- effectiveness ratios than in the current 
report.23
Several important trends in obstetric and neonatal care 
practices were noted over the 25 years. Lower proportions 
Figure 2 Additional days of respiratory support (ventilation) 
relative to extra infant survival for years 1991–1992, 1997, 
2005 compared with 2016–2017.
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of stillbirths, more antenatal corticosteroid therapy, and 
more caesarean births reflect a more positive obstetric 
attitude towards active management of EP births. The 
changing attitudes towards more intensive care for infants 
born EP after birth, evident before the 1990s,24 continued 
in the current study, from 78% in 1991–1992 to 88% in 
1997, with rates remaining relatively unchanged ever 
since. We were unable to source data from other regions 
on changing attitudes to intensive care from comparable 
EP cohorts to allow for direct comparisons. In the USA, 
a comparison of three epochs from 2000 to 2011 did 
not demonstrate changes in active treatment for infants 
born 22–24 weeks gestation, which was offered to 74% of 
births.4 In the EXPRESS cohorts in Sweden comparing 
births at 22–26 weeks between 2004–2007 and 2014–2016, 
rates of a neonatologist attending the birth, which may 
reflect the intention to offer intensive care following 
delivery, were high for both epochs at 83% and 84% of 
all births, respectively.25 The EPICure (UK) and EPIPAGE 
(France) groups had consecutive cohorts of births 22–26 
weeks gestation from 1995 and 2006, and 1997 and 2011, 
respectively, but reported data on active stabilisation for 
the latter of their cohorts only; for EPICure it was 91% of 
births,5 and for EPIPAGE-2 it was 78%.26
We noted a decrease in births within a tertiary neonatal 
centre. The reasons for this are likely to be multifacto-
rial and include decision making around resuscitation 
of EP infants born <25 weeks gestation, geographical 
factors (distance to the nearest tertiary centre, precipi-
tous births and births before arrival) and delay in/missed 
opportunities for in utero transfer. In the state of Victoria, 
there has been a dedicated transport service for pregnant 
women at risk of preterm birth as well as sick preterm 
newborns since the mid- 1970s. Inborn infants have less 
mortality and morbidity than infants born elsewhere.27 28 
The decrease in cystic periventricular leukomalacia by 
almost 80% over time is similar to reports from other 
cohorts,19 20 25 although rates of IVH grades 3–4 remained 
unchanged. We have previously reported that rates of 
IVH grades 3–4 were higher in EP infants who were born 
outside a tertiary neonatal centre compared with those 
who were (20% vs 11%).29 The increase in rates of EP 
births outside a tertiary centre over eras may have contrib-
uted to the lack of decrease in rates of IVH grades 3–4 
over time.
The duration of oxygen therapy was longer in the 2016–
2017 cohort compared with all earlier cohorts, which 
makes the decrease in BPD between 2005 and 2016–2017 
difficult to interpret. The longer duration of oxygen in 
2016–2017 compared with earlier eras may have been due 
to increased oxygen saturation targets, an unintended 
consequence of higher oxygen saturation targets from 
several large randomised- controlled trials of oxygen satu-
ration targeting in EP infants,6 30 which reported higher 
survival rates favouring oxygen saturation targets of 
91%–95% compared with 85%–89%. The higher oxygen 
saturation targets in 2016–2017 may also be related to the 
higher rates of ROP requiring treatment in 2016–2017, 
a finding similar to that reported from an individual 
participant data meta- analysis of five oxygen saturation 
target trials in EP infants.9 Increased treatment of ROP 
over time could also be explained by lower thresholds for 
intervention with more emphasis on ‘Plus’ disease.31
Major strengths of our study are the sequential cohorts 
from the same defined geographical area, with uniform 
data collection by experienced teams, and standards of 
care that are consistent within the region at any one time. 
A limitation is that all methods for respiratory support 
are weighted equally in determining cost- effectiveness. 
However, since all forms of respiratory support require an 
intensive care cot, we have made the conscious decision 
not weight the different methods to allow us to calculate 
the intensive care cot requirements to increase survival. 
We were also unable to determine changing rates of 
BPD using more contemporary definitions because such 
criteria were not present when the older cohorts were 
recruited.
CONCLUSION
Over the first 25 years since surfactant was available 
for use for EP infants in Australia, we observed short- 
term improvements, especially for survival to discharge 
home, but with an escalation in the resources for respi-
ratory support. How these changes translate into long- 
term respiratory or neurological function remains to be 
determined.
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